Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular ...

Morpheus is committed to ensuring that builders are also recognized for their hard work, not just agents or compute providers The platform employs a distribution ...